The main clinical manifestations of the disease contain immunodeficiency, hyperproteinemia, renal disorder, bone lesions and pancytopenia. Although patients suffering from MM may initially respond to chemotherapy, they ultimately become immune to this kind of therapy. Only complete remission is achieved by 5% of GSK-3 inhibition patients, and the median survival is 30?36 weeks. Consequently, more effective and less toxic treatment options are essential in the battle against MM. Multiple signaling cascades, like the Janus household tyrosine kinase /signal transducer and activator of transcription proteins, the Ras/Raf/Mek/Erk and the phosphatidylinositol 3 OH kinase /Akt pathways, are activated in MM. The PI3 K/Akt path is of particular interest due to the role in suppressing apoptosis and promoting cell proliferation. In Multiple Myeloma, insulin like growth factor 1 stimulates PI3 K/Akt pathway, resulting in both proliferative and anti apoptotic effects. The inhibitors of CTEP GluR Chemical apoptosis proteins Lymph node are a category of intracellular anti apoptotic proteins that play a key role in cell survival by modulating death signaling pathways at the postmitochondrial stage. Survivin is just a member of the IAPs meats, which becomes the next most stated transcript in human cancer, however not in normal tissues. As regulator of cell cycle and It’s dual task as inhibitor of apoptosis. Recent studies show that survivin gets the capability to prevent the main element molecules of the apoptotic equipment, the caspases and is just a downstream target in both JAK/STAT and PI3 K/Akt paths. The non harmful immunomodulator Ammonium trichloro tellurate, first developed by us, is a low molecular weight organic tellurium compound. AS101 get immunomodulating properties and have beneficial effects in various pre clinical and clinical studies. In a variety of tumor models, AS101 map kinase inhibitor has been found to truly have a clear anti tumor properties. AS101 was demonstrated to improve the success of Madison lung carcinoma showing mice when given in combination with chemotherapy. In still another study, combined treatment of AS101 with low doses of paclitaxel enhanced survival of B16 melanoma tumefaction bearing rats by up controlling Fas/Apo 1 expression. Phase I clinical trials on advanced level cancer patients treated with AS101 showed increased production and release of a number of cytokines, ultimately causing a clear dominance in the Th1 response with a reduction in the Th2 response. Phase a significant reduction has been shown by II clinical trials in non small lung cancer patients treated with AS101 in combination with chemotherapy in the severity of thrombocytopenia and neutropenia that accompanies chemotherapy. The majority of AS101 activities have been largely related to the direct inhibition of the anti inflammatory cytokine IL 10.